ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Imidazole Post-Treated Self-Assembled Monolayers for Inverted Perovskite Solar Cells.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Inverted perovskite solar cells have emerged as promising candidates for next-generation photovoltaics due to their compatibility with tandem architectures and flexible substrates. A critical factor for high device performance is the optimization of buried interfaces using self-assembled monolayers (SAMs), with Me-4PACz standing out for its excellent charge extraction properties. However, a polarity mismatch between the hydrophobic carbazole terminal and the polar perovskite precursors hinders film coverage and efficient device reproducibility. Here, we report a facile post-treatment strategy employing two chlorinated imidazole derivatives, 4,5-dichloroimidazole (4,5-DI) and 4,5-dichloro-2-methylimidazole (4,5-D-2-MI), at the Me-4PACz/perovskite interface. These molecules enhance carbazole-imidazole interactions, convert the surface from nonpolar to polar, and improve the wettability of the SAM, resulting in an enhanced perovskite morphology. The resulting interfacial dipole modifications alter the work function and reduce the band offset at Me-4PACz/perovskite interface, ultimately enhancing the device fill factor and photovoltage. Ultimately, the target devices delivered an efficiency of approximately 25% with improved long-term stability under varied environmental conditions, highlighting the effectiveness of interfacial engineering via SAM post-treatment for high-performance and durable devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.